A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats

Journal of Pharmaceutical Sciences

Volumn 91, Issue 12, 2002, Pages 2500-2510

  Perlstein, Itay ^a   Stepensky, David ^a   Krzyzanski, Wojciech ^b   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Atropine; Heart rate variability; Pharmacodynamics; Pharmacokinetics; Power spectral analysis; Scopolamine; Signal transduction model

Indexed keywords

ATROPINE; SCOPOLAMINE; CHOLINERGIC RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; AUTONOMIC INNERVATION; BOLUS INJECTION; CHOLINERGIC ACTIVITY; CHOLINERGIC STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG RESPONSE; ELECTROCARDIOGRAM; HEART RATE VARIABILITY; MALE; MODEL; NONHUMAN; PARASYMPATHETIC NERVE; PHARMACODYNAMICS; QUANTITATIVE ANALYSIS; RAT; RR INTERVAL; SIGNAL TRANSDUCTION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; BLOOD; CHEMICAL MODEL; DOSE RESPONSE; DRUG EFFECT; PHYSIOLOGY;

ANIMALS; ATROPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PARASYMPATHOMIMETICS; RATS; SCOPOLAMINE; SIGNAL TRANSDUCTION;

EID: 0036893416     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10243     Document Type: Conference Paper

References (40)

1. Cripps TR, Malik M, Farrell TG, Camm AJ. 1991. Prognostic value of reduced heart rate variability after myocardial infarction: Clinical evaluation of a new analysis method. Br Heart J 65(1):14-19.
2. Bigger JTJ, Fleiss JL, Rolnitzky LM, Steinman RC, Schneider WJ. 1991. Time course of recovery of heart period variability after myocardial infarction. J Am Coll Cardiol 18(7):1643-1649.
3. Kleiger RE, Miller JP, Bigger JTJ, Moss AJ. 1987. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59(4):256-262.
4. Malik M. 1996. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93(5):1043-1065.
5. La-Rovere MT, Mortara A, Pantaleo P, Maestri R, Cobelli F, Tavazzi L. 1994. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 90(2):838-843.
6. Pedretti R, Colombo E, Sarzi-Braga S, Caru B. 1993. Influence of transdermal scopolamine on cardiac sympathovagal interaction after acute myocardial infarction. Am J Cardiol 72(5):384-392.
7. Brown JH, Taylor P. 1996. Muscarinic receptor agonists and antagonists. In: Hardman J, Goodman-Gilman A, Limbird L, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th Edition. New York: McGraw-Hill, 1996. pp 141-159.
8. Derendorf H, Meibohm B. 1999. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives. Pharm Res 16(2):176-185.
9. Berntson GG, Bigger JTJ, Eckberg DL, Grossman P, Kaufmann PG, Malik M, Nagaraja HN, Porges SW, Saul JP, Stone PH, van-der-Molen MW. 1997. Heart rate variability: Origins, methods, and interpretive caveats. Psychophysiology 34(6):623-648.
10. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. 1981. Power spectrum analysis of heart rate fluctuation: A quantitative probe of beat-to-beat cardiovascular control. Science 213(4504):220-222.
11. Malliani A, Pagani M, Lomardi F, Cerruti S. 1991. Cardiovascular neural regulation explored in the frequency domain. Circulation 84(2):482-492.
12. Pomeranz B, Macaulay RJ, Caudill MA, Kutz I, Adam D, Gordon D, Kilborn KM, Barger AC, Shannon DC, Cohen RJ, Benson M. 1985. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 248:H151-H153.
13. Houle MS, Billman GE. 1999. Low-frequency component of the heart rate variability spectrum: A poor marker of sympathetic activity. Am J Physiol Heart Circ Physiol 276:H215-H223.
14. Perlstein I, Hoffman A. 2000. Cumulative plot of heart rate variability spectrum assesses kinetics of action of cholinergic drugs in rats. Am J Physiol Heart Circ Physiol 279:H110-H115.
15. Stanton A, Cox J, Atkins N, O'Malley K, O'Brien E. 1992. Cumulative sums in quantifying circadian blood pressure patterns. Hypertension 19:93-101.
16. Royston R. 1992. The use of cusums and other techniques in modeling continuous covariates in logistic regression. Statistics Med 11:1115-1129.
17. Perlstein I, Hoffman A. 2000. The cumulative plot of power spectral analysis of heart rate variability assesses the kinetics of action of cholinergic drugs in rats. 2000 World Congress on Medical Physics and Biomedical Engineering. Chicago, IL.
18. Sapoznikov D, Luria MH, Mahler Y, Gotsman MS. 1992. Computer processing of artifact and arrhythmias in heart rate variability analysis. Comput Methods Programs Biomed 39(1-2):75-84.
19. Sapoznikov D, Luria MH, Gotsman MS. 1993. Comparison of different methodologies of heart rate variability analysis. Comput Methods Programs Biomed 41(2):69-75.
20. Aaltonen L, Kanto J, Iisalo E, Pihlajamaki K. 1984. Comparison of radioreceptor assay and radioimmunoassay for atropine: Pharmacokinetic application. Eur J Clin Pharm 26(5):613-617.
21. Sun YN, Jusko WJ. 1998. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87(6):732-737.
22. Mager DE, Jusko WJ. 2001. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70(3):210-216.
23. D'Argenio DZ, Shumitzky A. 1997. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software, Los Angeles, CA: Biomedical Simulations Resource.
24. Muzi M, Ebert TJ. 1993. Quantification of heart rate variability with power spectral analysis. Curr Opinion Anaesthesiol 6:3-17.
25. Pagani M, Malfatto G, Pierini S, Casati R, Masu AM, Poli M, Guzzetti S, Lombardi F, Cerutti S, Malliani A. 1988. Spectral analysis of heart rate variability in the assessment of autonomic diabetic neuropathy. J Auton Nerv Syst 23(2):143-153.
26. Freeman R, Saul JP, Roberts MS, Berger RD, Broadbridge C, Cohen RJ. 1991. Spectral analysis of heart rate in diabetic autonomic neuropathy. A comparison with standard tests of autonomic function. Arch Neurol 48(2):185-190.
27. Donchin J, Constantini S, Szold A, Byrne EA, Porges SW. 1992. Cardiac vagal tone predicts outcome in neurosurgical patients. Crit Care Med 20:942-949.
28. Holford NH, Sheiner LB. 1981. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit Rev Bioeng 5(4):273-322.
29. Holford NH, Sheiner LB. 1982. Kinetics of pharmacologic response. Pharmacol Ther 16(2):143-166.
30. Sharma A, Jusko WJ. 1996. Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 24(6):611-635.
31. Jusko WJ, Ko HC. 1994. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56(4):406-419.
32. Xu ZX, Sun YN, DuBois DC, Almon RR, Jusko WJ. 1995. Third-generation model for corticosteroid pharmacodynamics: Roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokinet Biopharm 23(2):163-181.
33. Ali-Melkkila T, Kaila T, Antila K, Halkola L, Iisalo E. 1991. Effects of glycopyrrolate and atropine on heart rate variability. Acta Anaesthesiol Scand 35(5):436-441.
34. Das G, Talmers FN, Weissler AM. 1975. New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man. Am J Cardiol 36(3):281-285.
35. Wellstein A, Pitschner HF. 1988. Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn Schmeideberg Arch Pharmacol 338(1):19-27.
36. Krzyzanski W, Jusko WJ. 1998. Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. J Pharmacokinet Biopharm 26(4):385-408.
37. Picker O, Scheeren TW, Arndt JO. 2001. Nitric oxide synthases in vagal neurons are crucial for the regulation of heart rate in awake dogs. Basic Res Cardiol 96(4):395-404.
38. Liu H, Terrell ML, Summy-Long JY, Kadekaro M. 1998. Brain ANG II and prostaglandins mediate the pressor response after central blockade of nitric oxide synthase. Brain Res 785:317-328.
39. Ali-Melkkila T, Kanto J, Iisalo E. 1993. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 37(5):633-642.
40. Kanto J, Kentala E, Kaila T, Pihlamjamaki K. 1989. Pharmacokinetics of scopolamine during caesarian section: Relationship between serum concentration and effect. Acta Anaesthesiol Scand 33:482-486.